Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.

导出原文传递

翻译打印收藏纠错

作者： Allison,Betof Warner ^[1] ; Ahmad,Tarhini ^[2] ; Barinder,Kang ^[3] ; Antonio,Nakasato ^[3] ; You-Li,Ling ^[3] ; Rohan,Shah ^[3] ; Jackson,Tang ^[4] ; Jeetvan,Patel ^[3]

作者单位： Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. ^[1] Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ^[2] Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. ^[3] Asclepius Analytics Ltd., New York, New York, USA. ^[4]

主题词人类(Humans);黑色素瘤(Melanoma);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);回顾性研究(Retrospective Studies);皮肤肿瘤(Skin Neoplasms);免疫疗法(Immunotherapy)

DOI 10.1097/CMR.0000000000000856

PMID 36545921

发布时间 2023-02-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交